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in the excision remnant kidney model
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INSERM U. 192, Hopiral Necker Enfants-Malades, Paris, France
Renal effect of anti-hypertensive drugs depends on sodium diet in the
excision remnant kidney model. Angiotensin converting enzyme inhibi-
tors (ACEI) are believed to protect remnant kidney, but all previous
studies used the ligation model which causes severe hypertension, and
very few have compared drugs in rats having similar control of blood
pressure (BP). We compared rats with uremia obtained by 70% excision
of total renal mass, a model which causes mild, late hypertension.
Study I compared the effects of enalapril (E), cicletanine (C) and
placebo (P) in uremic (U) rats fed a 0.50% (normal-high) Na diet. Study
II compared the effects of E, C, P. and guanfacine (0) in U rats fed a
diet restricted to 0.25% Na (normal-low). In study I, UP rats developed
progressive hypertension (140, 146, 160 and 166 mm Hg at 3, 6, 9 and 12
weeks), proteinuria (240 mg/day at 9 and 12 weeks) which were not
affected by E or C. The occurrence of end-stage renal disease (ESRD)
led to the sacrifice of all rats after three months. All three groups had
similar severe renal lesions (over 25% sclerosed glomeruli in 5 of 10 UP,
9 of 14 UE, 7 of 14 UC rats, with huge cystic tubular dilatations). In
study II, rats could be sacrificed later (6 months) and had evidence of
less severe renal disease. All the drugs tested prevented hypertension
throughout the study (P < 0.001), with lowest values in UE rats. E and
0, but not C, reduced proteinuria. Renal damage was reduced with E
and G, but not with C, despite similar BP in C and 0 rats. Thus, in
contrast with what was obtained in the ligation model, ACEI affected
neither the BP nor the renal lesions of rats made uremic by renal
excision and fed a 0.50% Na diet. Moderate Na restriction improved the
consequences of nephron loss and restored the anti-hypertensive effect
of drugs. However, these drugs had a different effect on renal preser-
vation: it was dramatic with B, good with G, and undetectable with C.
Several studies published over the past decades have pro-
vided convincing experimental evidence for the progressive
development of renal lesions in the remnant kidney after severe
renal ablation [1—3]. It has also been shown that several
therapeutic maneuvers, including dietetic changes and drugs,
influence the rate of kidney deterioration, suggesting that the
evolution towards end-stage renal disease (ESRD) may be
retarded [4, 51.
Slowing the progression of renal damage has thus become a
priority for experimental and clinical research, even if the
relevance of the experimental findings to the human disease is
disputed [6, 7]. There is, however, evidence that initially
normal nephrons are gradually destroyed in patients with a
severely reduced number of nephrons, particularly in some
pediatric conditions, such as oligomeganephronic hypoplasia
[8] or the sequelae of obstructive uropathies [9]. Nephron
reduction may also play a role in other renal diseases leading to
ESRD [10], but its importance varies according to the effects of
other factors, such as the persistence of the initial process and
hypertension.
Although others have been implicated [4, 5], the two most
important factors that improve the rate of renal deterioration in
the experimental models are reduction of protein intake [11—14]
and administration of angiotensin converting enzyme inhibitors
(ACEI) [15]. Both affect intrarenal hemodynamics [12, 15]
and/or nephron hypertrophy [16, 17], suggesting that the main
mechanism(s) involved are intraglomerular pressure and as-yet-
unidentified growth factors.
The potent anti-hypertensive effect of ACEI may play a role
in renal protection (Table 1) [15, 17—26]. To date, the effect of
ACEI on severe nephron reduction has been studied only in the
model obtained by ligating the branches of the renal arteries
which induces an early and severe hypertension. Very few
studies (Table 1) have compared the effects of ACEI with those
of other anti-hypertensive drugs, providing similar control of
blood pressure, and thus determining whether ACEI have
specific effects.
This study was carried out to determine whether ACEI have
a higher renal protective effect than other anti-hypertensive
drugs in the remnant kidney excision model where hypertension
is less severe or develops later in the course of the disease than
in the ligation model. The inefficacy of ACEI in a first experi-
mental setting was unexpected and contrasted with all reports
using the ligation model. This led us to conduct a second
experiment with moderate sodium (Na) restriction. Both Na
diets remained within the range normally used in some labora-
tories. The second study showed that Na reduction had its own
beneficial effect and restored the efficiency of the anti-hyper-
tensive drugs used, with varying consequences on renal dam-
age.
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Animals
Male Wistar rats (Iffa Credo, France), aged five weeks and
weighing 120 to 130 g were allowed to adapt to the laboratory
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Table 1. Protective effect of anti-hypertensive drugs on the
progression of renal lesions in nephron reduction
Author Year ACEI
Triple
Tx
Ca channel
blockers
Anderson 1986 +++ 0 ND
Jackson 1988 +++ ND 0
Yoshida 1989 +++ +++ ND
Brunner 1989 +++ (0.6% Na)
++++ (0.1% Na)
ND
ND
Worsening
Worsening
Anderson 1985 + + + ND ND
Meyer 1987 +++ ND ND
Beukersa 1987 +++ ND ND
Jackson 1987 ++ ND ND
Purkerson 1976 ND ++ ND
Harrisb 1987 ND ND +
Pelayo 1988 ND ND 0
Abbreviations are: Triple Tx, triple therapy (hydralazine + reserpine
+ hydrochlorothiazide); ND, not done.
a Uninephrectomy
b Excision model
for five days prior to surgery. Subtotal nephrectomy was
performed under pentobarbital anesthesia (54 mg/kg body wt).
The right kidney was decapsulated, removed and weighed. The
two poles of the left kidney were excised with scissors. Left
renal ablation was adjusted to obtain a 70% reduction by weight
of total renal mass, assumed to be twice that of the right kidney.
Control rats underwent sham operation with renal decapsula-
tion. Following surgery, the rats were kept for four days on a
diet containing 10 g/lOO g (%) casein and 0.50% sodium, to allow
them to recover from surgical stress and acute renal failure.
They were then switched to the experimental diet.
The diet used in study I contained 0.50% sodium, as in the
usual laboratory chow; Na was reduced to 0.25% in study II, by
reducing sodium chloride from 0.38 to 0%, and sodium phos-
phate from 2.34 to 1.67%. Phosphorus and calcium concentra-
tions were kept identical (0.55 and 0.53%) by altering CaPO4
and CaCO3. Both diets contained 20% casein, 27.5% corn-
starch, 32% sucrose, 10% corn oil, 4.8% cellulose, 1% vitamins,
and 4.7% mineral mixtures, providing 0.5% K and 0.1% Mg.
The two diets were given ad libitum.
Six days after surgery, the rats in both studies were matched
for body weight and distributed into treatment groups. In study
I three treatments were used in both control and uremic rats: an
ACE!, enalapril (E) (Merck, Sharp Dohme & Chibret), at 3.0
mg/kg/day; a new vasodilating agent, cicletanine (C) (Ipsen-
Beaufour), at 4.2 mg/kg/day; and placebo (P) (10% glucose
solution). The same treatments were used for control and
uremic rats in study II. A group treated with an a2 adrenergic
receptor-stimulating agent, guanfacine (G) (Sandoz), at 5.0
mg/kg/day, was added to get further insight on the relation
between blood pressure (BP) control and renal deterioration.
Drugs were dissolved in 0.5 mlIlOO g body wt of 10% glucose
solution, except for cicletanine which was dissolved in gum
arabic and water. They were administered by daily gavage in
the morning. The daily dose of each drug was progressively
increased to reach the final dose after one week in both
experiments. Gavage with a 5% glucose solution was begun two
days before surgery so that the rats became accustomed to
manipulation.
Groups of 15 uremic rats were scheduled in both studies. A
Table 2. Experimental protocol
Study I Study II
(0.50% Na diet) (0.25% Na diet)
Control (N) Uremic (N) Control (N) Uremic (N)
Placebo 8 13 4 10
Enalapril 8 15 4 15
Cicletanine 8 14 4 13
Guanfacine — — 4 13
few rats died early from renal bleeding and/or urethral obstruc-
tion, or from anesthesia, but apparently from non-renal disease,
since they had normal kidneys. The number of rats followed
throughout the experiment is indicated in Table 2.
The animals were kept in a room with a constant ambient
temperature and a 12 hour light-dark cycle, and had free access
to tap water.
All rats were weighed three times a week. A preliminary pilot
study showed identical food consumption by all uremic rats,
regardless of the drugs administered.
BP was measured under light ether anesthesia, using an
electrosphygmomanometer PE 300 (Roucaire, France) by the
tail-cuff method. Measurements were made every three
weeks, in the morning before drug administration. In our experi-
ence values obtained in the awake state were slightly higher
(10 mm Hg) but parallel to those found under light ether
anesthesia, regardless of the drug used. At sacrifice BP was also
measured through intra-femoral catheter under pentobarbital
anesthesia in all groups: values were slightly lower but parallel
to those found by the tail-cuff method.
Under ether anesthesia, blood samples were taken from the
jugular vein of rats every three weeks to measure hematocrit,
plasma creatinine (Per), urea, calcium, phosphorus, total pro-
tein, electrolyte, triglycerides and cholesterol levels. All rats
were kept for 24 hours in metabolic cages for urine collection
once every three weeks in study I, and once every six weeks in
study II.
All plasma determinations were performed with a multipara-
metric automatic analyzer, HITACHI 717 (Boehringer,
France). Urine samples were analyzed for urea, creatinine and
electrolytes with S.M.A. autoanalyzer and for protein by the
biuret method.
In a few rats of study I, ACE was measured as previously
described [271.
Both studies were designed to be terminated after six months,
with earlier sacrifice of animals which seemed moribund. In
study I, four UE and four UC rats died at the end of the third
month with ESRD, as shown by plasma creatinine levels (>300
prnol/liter) and by renal histology. The surviving rats appeared
very ill and all rats were sacrificed after three months. The
mortality rate was lower in study II and the study was termi-
nated after six months, when two UP, one UC and one UG died
with ESRD. The longer follow-up was chosen because a too
short observation in the presence of slow deterioration could
hamper detection of differences between groups.
The remnant kidney of uremic rats and the left kidney of
control rats were removed at the time of sacrifice and weighed.
They were fixed in formalin (15%), embedded in paraffin, cut at
356 Terzl et at: Anti-hypertensive drugs and renal deterioration
Table 3. Data at time of sacrifice in study 1(0.50% Na)
Group N
Body
weight
Left kidney
weight Ccr
mt/mm
1Ure Cholesterol Hct
%
Tota
proteins
gluiermmol/liierg
CP 8 434 15 1.37 0.15 2.53 0.12 6.6 0.7 2.16 0.20 47 1 60 I
UP 13 374 14 3.00 0.48 0.95 0.13 23.2 4.1 4.47 0.70 38 2 52 1
UE 15 385 8 4.12 0.68 1.15 0.14 22.9 3.3 4.23 0.70 39 2 52 1
UC 14 361 15 3,01 0.40 0.93 0.15 26.2 4.5 4.25 0.53 38 2 52 1
Abbreviations are: C, control rats; U, uremic rats; P, placebo; B, enalapril; C, cicletanine. Values of all control rats were similar and only values
of CP group are shown.
One-way ANOVA showed P values from 0.2 to 0.9 for all parameters in uremic rats.
3 m and stained with hematoxylin and eosin, with periodic
acid Schiff, Masson trichrome and von Kossa techniques.
All sections were evaluated semi-quantitatively using a blind
technique. The following parameters were assessed: (1) seg-
mental or global sclerosis andlor hyalinosis for glomerular
damage (expansion of mesangial matrix alone was not taken
into account); (2) tubular lesions, and more specifically tubular
microcystic dilatation with protein or hyalin casts; (3) presence
of calcium deposits; and (4) vascular lesions involving arterioles
and small interlobular arteries.
One hundred glomeruli from each kidney were scored for the
presence or absence of significant damage. The glomeruloscle-
rosis index was the percentage of glomeruli with sclerosis or
hyalinosis. The tubular and vascular lesions and calcium depos-
its were scored (0, +, ++, +++) according to their severity
and diffusion. For tubular lesions: 0 = well preserved renal
cortex without tubular lesions; + = scattered foci of mild
tubular dilations; + + = numerous area of tubular dilations;
+ + + = diffuse and severe tubular dilations. For vascular
lesions: 0 = normal vessels; + = mild intimal thickening
affecting a few arterioles; + + = intimal thickening with reduc-
tion of arteriolar lumen involving numerous vessels; + + + =
necrotizing arteriolitis, or considerable intimal thickening with
obliteration of the vascular lumen affecting nearly all vessels.
Glomerular surface was measured on PAS stained sections
by a semi-automatic method which used a microscope equipped
with a drawing tube and a digitizing platen connected to a
computer. Sections were screened moving from cortex to
medulla and vice-versa. A total of at least 10 glomeruli per
animal was scored.
A pilot experiment was performed between study I and study
II to compare the two Na diets, to insure they had similar
effects on food intake and weight in control (3 per group) and
uremic rats (7 per group), and to validate comparisons between
the conditions of experiments I and II when performed simul-
taneously. These rats were sacrificed after 12 weeks, and
underwent the same investigations as those of studies I and II.
Plasma renin activity (PRA) was also measured three and six
weeks after nephrectomy, by radioimmunoassay of angiotensin
I using the antibody trapping method at pH 7.4 [281.
Statistical analysis
All results are expressed as means SEM. Statistical analyses
[29] were performed to assess the effect of drugs on blood
pressure, unnary proteins and renal lesions in the uremic rats of
study I and study II. A chi square test was performed for
qualitative data; analysis of variance (ANOVA) for repeated
measurements was done to compare blood pressure and urinary
protein excretion. If it was significant, it was followed by a
one-way ANOVA test to compare the final values. When the
latter was significant, they were compared to the placebo group
using the Dunnett test, and with the other groups by the Scheffe
test. Less essential comparisons using one-way ANOVA fol-
lowed by Dunnett and Scheffe tests were performed on other
data related to renal function. Control rats served as reference
and were not taken into account for statistical analysis.
Results
Study I
The body weight of the rats in all uremic groups was similar,
regardless of treatment, and was slightly lower than those of the
control rats (Table 3).
Cr and plasma urea levels were markedly higher in uremic
than in control rats, but showed no significant difference
ascribable to treatment. Cr was 60% lower in uremic rats than
in control rats, regardless of therapy.
Plasma sodium, potassium, chloride, bicarbonate and cal-
cium were normal in all groups. The mean plasma phosphorus
levels showed the same increase in all uremic rats (mean values:
2.49 0.30 in uremic vs. 1.60 0.03 mmollliter in control rats).
Total plasma protein levels were slightly lower in uremic than in
control rats, as was the hematocrit. Plasma triglycerides were
identical in all control and uremic rats. Plasma cholesterol
levels were higher in uremic rats. None of these parameters was
affected by the drugs.
The evolution of BP is shown in Figure la. The BP of controls
remained around 120 mm Hg, and was moderately reduced by
enalapril. The BP of uremic rats rose as early as by week 3, but
the rise was small and was identical in all groups. All groups
developed severe hypertension after the ninth week, which
persisted until the end of the study. BP was higher in enalapril-
treated uremic rats than in the other groups, but the difference
was not significant.
The urinary protein excretion (Fig. 2a) of uremic rats was
higher than that of control rats at all determinations. There was
no significant difference within the uremic groups.
Kidney weight was unchanged by the drugs in control rats.
The renal mass of the remnant kidney increased dramatically
with kidney weight reaching two to three times that of one
normal kidney (Table 3). The remnant kidneys all looked alike
regardless of treatment, and all had a cystic appearance.
The results of histologic examination are summarized in
Table 4. Control rats had normal kidneys. Most uremic rats had
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Fig. 1. Blood pressure changes in studies land!!. Abbreviations are: C, control rats; U, uremic rats; P. placebo; E, enalapril; C, cicletanine; G,
guafacine. Symbols are: (•-.) UE; (-•-) UP; (A--) UC; (-LTJ-) CP; (•) UG. A. Study 1(0.50% Na diet). All uremic rats developed progressive
hypertension with no statistical difference between groups (ANOVA for repeated measurements). B. Study 11(0.25% Na diet). Only UP rats
developed moderate hypertension. BP did not differ from control values in UC and UG rats. E resulted in lower BP than the other drugs.
Comparison between uremic rats: ANOVA for repeated measurements, P < 0.001; ANOVA for final values, P < 0.001; UP vs. UC, UG, UE, P
<0.05 (Dunnett test); UE vs. UC, UG, P <0.05 (Scheffe test).
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Fig. 2. Urinary protein excretion in studies land!!. Abbreviations are: C, control rats; U, uremic rats; P. placebo; E, enalapril; C, cicletanine;
G, guanfacine. Symbols are: (•-.) UE; (-s-) UP; (A--) UC; (-D-) CP; (..•.) UG. A. Study 1(0.50% Na diet). All uremic rats had increased protein
loss, with no statistical difference between group (ANOVA for repeated measurements). B. Study 11(0.25% Na diet). Among uremic rats, UP and
UC rats developed a progressive increase in protein excretion, which remained lower than in study I. Protein excretion was significantly lower in
UE and UG rats. Comparison between uremic rats: ANOVA for repeated measurements, P < 0.001; ANOVA for final values, P < 0.02; UP vs.
UE, UG, P < 0.01 (Dunnett test).
developed glomeruloscierosis, with lesions affecting 25% or in all but four rats that had moderate (+) alterations. Some
more of the glomeruli in half the animals. Normal tubules were calcium deposits were found in most uremic rats. The appear-
exceptional. Tubular dilation was dramatic in the majority of ance and severity of the renal lesions were essentially the same
uremic rats (Fig. 3a). By contrast, vascular damage was absent in all uremic groups, regardless of the drug administered.
I
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Table 4. Renal lesions and glomerular surface in rats of study I (0.50% Na) at time of sacrifice
Group N
Glomeruloscierosis % Tubular dilation Glomerular
surface wn20 + ++ +++0 0—10 10—25 25—50 >50
CP
UP
UE
UC
8
10
14
14
8
3
1
1
0
0
3
2
0 0
2 1
1 7
4 4
0
4
2
3
8
1
2
2
0 0
3 2
2 5
3 5
0
4
5
4
7417 315
15284 590
17171 1332
17880 2557
Abbreviations are: C, control rats; U, uremic rats; P, placebo; E, enalapril; C, cicletanine. The histologic study was not performed on 3 UP and
1 UE rats because of technical problems. Morphometry was performed in 5 rats per group. The differences between uremic groups were not
significant.
Fig. 3. Histological appearance of the kidneys from two groups of uremic rats. A. Kidney of a UE rat in study 1(0.50% Na diet). It shovs cystic
tubular dilations and glomerular sclerosis. The lesions were similar in the other uremic groups in study I. B. Kidney of a UE rat in study 11(0.25%
Na diet). The kidney is almost normal kidney, indicating the beneficial effect of E in the presence of moderate Na restriction.
Glomerular surface (Table 4) of non-sclerotic glomeruli was activity was dramatically reduced in both the control and the
dramatically increased (by 100 to 140%) in uremic compared to uremic rats given enalapril (mean values: 4.0 in E treated rats
control rats, with no effect of treatments. vs. 80.3 nmol/minfml in P treated rats).
The absence of detectable effects of enalapril led us to verify
that the dose used or the drug sample was not defective. The Pilot study
same dose was given, in the same way, to six SHR rats: it The pilot study showed that the change in Na diet from 0.50%
resulted in a drop of blood pressure in all animals, from 174 to 0.25% induced no significant difference in food intake, growth,
6 to 135 6 mm Hg. Moreover, the plasma converting enzyme and biological parameters. In the uremic rats the reduction in
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Table 5. Glomerular surface in the pilot study
Group N
Dietary Na
%
Glomerular
surface2
Controls
Uremics
3
5
0.50
0.50
7883 365
16884 1317
Controls
Uremics
3
6
0.25
0.25
7967 455
13940 725
a Uremic rats fed 0.25% Na diet vs. uremic rats fed 0.50% Na diet: P
< 0.05 (t-test)
dietary Na resulted in lower BP (144 vs. 157 mm Hg), lower
urinary protein loss (92 vs. 220 mg/day) lower remnant kidney
weight (2.00 vs. 2.41 g), less glomerular sclerosis and smaller
glomerular surface (Table 5). The PRA of uremic rats was lower
than in control rats on both diets (Table 6). However, the lower
dietary Na enhanced the PRA levels in both uremic and control
rats.
All values in control and uremic rats fed the 0.50% Na diet
were similar to those found in study I. Rats fed the 0.25% Na
diet were identical to those of study II for all parameters which
could be measured after 12 weeks in the latter experiment.
Study II
Body weight (Table 7) showed no apparent difference be-
tween treatment groups, except for rats treated by guanfacine.
At the time of sacrifice, the UE rats had slightly higher
creatinine clearance and slightly lower plasma urea and phos-
phorus levels than the other groups. Electrolyte, calcium and
triglycerides plasma levels were normal in all groups. Plasma
cholesterol was higher in uremic than in control rats, particu-
larly in UP and UC rats. The mean plasma total protein
concentrations were slightly reduced in the uremic groups,
except for UE rats, and the mean hematocrit marginally lower
than that of control rats.
The evolution of BP is represented on Figure lb. Although
none of the uremic rats developed severe hypertension, there
were clear differences between groups. The BP of UP rats was
normal three weeks after nephrectomy, and increased progres-
sively to reach a mean value of 150 8 mm Hg at the end of the
study. By contrast, hypertension occurred in none of the
treated rats. BP was identical to control values in UC and UG
rats, whereas UE rats had lower BP.
Urinary protein excretion increased progressively in the UP
and UC groups to values above those of UG and UE rats, as
shown in Figure 2b.
The kidney weight of control rats was similar to those of the
controls in study I. The weight of remnant kidney in uremic rats
was higher than that of a single control kidney. The increment
was greater in UP than in UE and UG rats and did not differ
from that of UC rats (Table 7). Few of the kidneys appeared
polycystic.
The results of histologic examination are shown in Table 8.
Control rats had normal kidneys. The severity of glomerular
and tubular damage in groups UP and UC were similar. The
kidneys of the UE rats (Fig. 3b) were remarkably well pre-
served; the kidneys of UG rats had more lesions than UE, but
less than the UP and UC rats. There was no vascular alteration,
and calcium deposits were found in only two UP rats.
Table 6. Plasma renin activity in pilot study
Group N
.
Dietary Na
%
PRA ng/ml/hr
3 weeks 6 weeks
Controls
Uremics
3
6
0.50
0.50
21.4 6.0
3.6 1.9
28.8 8.1
3.4 1.9
Controls
Uremics
3
7
0.25
0.25
35.8 1.3
13.0 3.9
38.5 6.5
10.2 3.0
Glomerular surface (Table 8) of non-sclerotic glomeruli was
markedly enhanced (by 55 to 75%) in uremic compared to
control rats. There was a trend for larger glomeruli in UP and
UC rats than in UE rats, but the difference was not statistically
significant.
Comparison between study II and study I
Comparison of biological data taken after similar duration (12
weeks) and of parameters measured at sacrifice of the study I
and II was used to analyze the consequences of different Na
feeding.
After 12 weeks, rats of study II has much lower BP and
proteinuria (Figs. 1 and 2) for all the groups considered. They
had lower blood urea (12 vs. 24 mmollliter), whereas they had
higher creatinine clearance (1. 17 vs. 1.00 ml/min), hematocrit
(44 vs. 38%) and plasma proteins (68 vs. 52 glliter).
At sacrifice, despite their longer survival, rats of study II had
lower blood pressure, protein excretion and remnant kidney
weight and fewer renal lesions, affording evidence for slower
progression of renal disease than rats of study I. In study II,
only one rat had more than 50% glomeruli with sclerosis,
whereas in study I, 9 of 38 rats had such extensive lesions. The
lower incidence of tubular dilations was particularly striking,
with only 4 of 49 rats having kidneys with a cystic appearance
in study II against 13 of 38 in study I. Glomerular surface area
was reduced in all uremic groups of study II compared to study
I. All these data are in agreement with those of the pilot study.
A striking feature was that in study I none of the drugs was
efficient on hypertension as well as on renal tissue, whereas in
study II, all of them normalized blood pressure but had different
effects on renal lesions.
Discussion
Study I showed a complete inefficacy of enalapril, at the dose
used, on the development of renal lesions. This is in complete
opposition with numerous previous reports examining the renal
effect of this drug in a variety of conditions, whether or not they
were associated with hypertension, all which concluded to the
beneficial effect of enalapril [301. Many of these studies [15, 17,
19—22, 25, 261 investigated the consequences of renal ablation,
and were performed in rats fed similar dietary Na (0.40 to
0.60%) as in study I.
This result was obtained despite a dose of enalapril similar to
those used previously, as far as can be estimated, since the
other authors gave the drug in drinking water. We preferred
daily gavage to achieve identical and constant treatment in each
animal, independent of diuresis and thirst, which vary with
renal function.
A possible explanation for the discrepancies observed lies in
the differences between the two models of renal ablation. All
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Table 7. Data at time of sacrifice in study 11(0.25% Na)
Group N
Body
weight
Left kidney
weight C,
mi/mm
P Cholesterol Hct
%
Total
proteins
gilitermmol/literg
CP 4 546 29 1.18 0.13 2.29 0.16 7.3 0.3 2.56 0.33 49 1 65 1
UP 10 484 20 2.64 0.65 1.14 0.20 22.9 5.8 3.95 0.38 39 3 57 2
UE 15 480 9 1.43 0.05" 1.53 0.10 13.9 0.6 2.94 0.13a 44 1 61 ta
UC 13 490 15 1.85 0.12 1.26 0.15 18.5 2.2 3.12 0.14 41 1 58 1
UG 13 410 7C 1.57 0.2l 1.29 0.10 15.9 3.4 2.62 0.14" 4't 1 55 1d
Abbreviations are: C, control rats; U, uremic rats; P, placebo; E, enalapril; C, cicletanine; G, guanfacine, Values of all control rats were similar
and only values of CP group are shown. Comparisons between uremic groups: vs. UP: a P < 0.05; bP < 0.01; C P< 0.001 (Dunnett test); vs. UE:
d P < 0.05; e p < 0.01 (Scheffe test).
Table 8. Renal lesions and glomerular surface in rats of study 11(0.25% Na) at time of sacrifice
Group N
Glomerulosclerosis % Tubular dilation Glomerular
surface pin20 + ++ +++0 0—10 10—25 25—50 >50
CP 4 4 0 0 0 0 4 0 0 0 7240 449
UP 10 1 2 5 1 1 1 4 4 1 12054 570
UE 15 12 2 1 0 0 9 4 2 0 11206 605
UC 11 1 2 4 4 0 1 6 2 2 12578 683
UG 13 5 5 2 1 0 4 7 1 1 11709 738
Abbreviations are: C, control rats; U, uremic rats; P. placebo; E, enalapril; C, cicletanine; G, guanfacine. The histologic study was not
performed on 2 UC rats because of technical problems. Morphometry was performed in 10 uremic and in 4 control rats per group. Histologic data:
differences between uremic groups: total chi square: P < 0.003; UE vs. UC and UP: P < 0.005.
previous studies comparing anti-hypertensive drugs in the rem-
nant kidney model used ligation of branches of renal arteries. A
shortcoming of this model is the severe, persistent hypertension
which appears immediately after ligation [15, 17—20, 22,24—26],
and which may play a role in renal deterioration [31]. It has
been strongly suggested that the early hypertension following
arterial ligation results from ischemia of renal tissue adjacent to
infarcted areas, and not from nephron reduction and renal
insufficiency [18, 32]. In the excision model we have used for
several years, blood pressure remains near normal, or at least
much lower than after ligation, during the first weeks or months
after surgery and sometimes until ESRD [33—37]. Our experi-
ence suggests that hypertension in this model is the conse-
quence rather than the cause of renal damage, since its devel-
opment follows that of glomerular sclerosis.
The differences in blood pressure do not depend on PRA
which is low in both models, at least in the chronic stage [15,
19]. It could depend on intrarenal renin which was found to be
high in the ligation model [38], and to be reduced in the excision
model [35]. The meaning of these findings remains to be
elucidated, but the inefficiency of ACEI suggests that renal
consequences of excision model are less dependent of the
angiotensin system than those of ligation model, at least in
normal dietary conditions.
Hypertension has been long considered as a major cause for
renal damage, but its role has been questioned. Intraglomerular
rather than systemic hypertension has been hypothetized to
play a role [12], and ACEI first have been used because they
specifically reduce intraglomerular pressure. ACEI indeed have
been shown to have a protective effect, even in experimental
renal disorders without hypertension [21, 39, 40]. The greater
benefit of ACE! over triple therapy [19], despite comparable
control of blood pressure, strengthened this hypothesis, but
other authors found a similar protective effect when higher
doses of triple therapy were used [17, 18]. Brunner et al [26]
observed a marked improvement of renal lesions with enalapril,
contrasting with enhanced damage in rats treated by verapamil,
but the latter had no effect on hypertension. Finally, if there is
a general agreement that ACEI have protective effects, the
benefit of other drugs remains controversial.
In our study enalapril was beneficial only in the presence of a
moderate Na restriction, when it was also efficient on blood
pressure. In this condition, its protective effect was quite
dramatic, with almost complete prevention of renal lesions over
six months. Only one study [26] has compared the effect of
drugs with two levels of dietary Na (0.6 and 0.1%) after arterial
ligation. It found that enalapril was beneficial in the two
conditions, with a greater effect on the low Na diet. Another
[41], performed in diabetic uninephrectomized SHR rats,
showed no effect of ACE! under Na loading.
The present study investigated the benefit of two other drugs:
cicletanine and guanfacine. Both drugs normalized blood pres-
sure in study II, but they had different effects on renal deteri-
oration, stressing the lack of relationship between hypertension
and development of renal lesions. The reason for the different
renal effects of C and G remains unclear. G rats had lower body
weight and plasma cholesterol levels, despite similar food
intake as the other groups, but they were hyperkinetic and
easily stressed, probably because of the high G dose used.
Glomerular hypertrophy has been shown to be better related
with glomerulosclerosis than intraglomerular pressure [42, 43].
Yoshida et al [17] showed that the beneficial effect of ACEI was
related to attenuation of glomerular hypertrophy rather than to
lower systemic and glomerular capillary hyperpressure.
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The present results showed a tendency for smaller glomeruli
with ACEI, but the difference in glomerular size was mild,
possibly because of too long an evolution after nephrectomy.
Therefore, ACE! diminished kidney enlargement mainly
through the reduction of tubular dilation as shown in Figure 3,
suggesting a prominent role in tubular events, possibly related
to hyperplasia, since angiotensin I! is recognized as a growth
factor with a possible mitogenetic effect [44].
As previously stressed, we found that enalapril efficiency
depended on Na diet, which is at variance with what is found in
the ligation model. Other studies showed that the two models
also differed by Na sensitivity of hypertension. In the excision
model hypertension is improved by Na restriction [35] and is
worsened by Na loading [33—35, 45]. By contrast, even more
severe dietary Na restriction does not seem to improve hyper-
tension in the ligation model [18, 46].
In the present study Na restriction resulted in a marked
protection of the remnant kidney. Whether this can be ascribed
mainly to less hypertension may be questioned. First, we may
recall that a human model of nephron reduction such as
congenital hypoplasia progresses to ESRD in the absence of
hypertension [8]. Second, progression of renal deterioration in
the present study occurred in the absence of vascular lesions.
Finally, other reports suggest that Na diet does not act exclu-
sively through blood pressure control. Several authors [18, 33,
34, 47] indicate enhanced glomerular damage when Na intake is
increased. Few reports [18, 46, 48] have examined the effect of
low Na diets. Daniels and Hostetter [46] demonstrated that
severe Na restriction (0.06% vs. 0.46%) reduces urinary protein
loss, glomerulosclerosis and glomerular hypertrophy in the
ligation model, despite unchanged systemic and glomerular
hypertension. Benstein et at [48] observed that an Na restricted
diet (0.09% vs. 0.45%) has a protective effect in uninephrecto-
mized SHR rats, which does not depend on blood pressure,
plasma renin concentration or glomerular hemodynamics, but
which is associated with less renal and glomerular hypertrophy.
They suggested that these effects are related to inhibition of
compensatory renal growth. In keeping with this hypothesis,
high dietary Na enhances in vivo renal hyperplasia and hyper-
trophy [49, 50] and a hypertonic saline medium enhances
tubular cell hypertrophy in vitro [51], whereas Na deficiency
slows kidney growth [52] as well as compensatory growth of
other organs [53] and inhibits tubular cell hyperplasia [54].
Our data show that even a much less severe Na reduction
induces a marked decrease in renal lesions. The protective
effect of a small change in dietary Na, remaining within the
normal range, has not been previously reported. The sodium
content of the normal-low Na diet used was about four times
higher than the minimal content required for normal growth [55,
56]. The marked reduction in glomerular hypertrophy and
tubular dilation and the absence of arteriolar alterations are in
agreement with a prominant role of growth factors [57] rather
than hypertension.
In the renal ablation models, as in the present study, protein-
uria is well related with progression of renal lesions [15, 19, 20,
23, 26]. It appears before, and increases with the development
of renal damage and depends on nonsclerotic glomeruli [58],
implying functional changes of the glomerular basement mem-
brane barrier. ACE! have been shown to have an immediate
effect on proteinuria [59], indicating a direct action on glomer-
ular basement membrane permeability. The latter probably
depends on the same mechanisms as the development of
lesions. However, whether proteinuria plays a role in or is a
consequence of renal deterioration remains unsolved [60].
Since the development of renal lesions may be affected by
plasma lipids levels [61, 62], we analyzed the effects of diet and
drugs on plasma triglycerides and cholesterol concentrations.
There was no evidence for a role of the former. The latter
showed a rough correlation with protein urinary loss (r =0.46),
suggesting enhanced cholesterol synthesis as observed in the
nephrotic syndrome. A role of high plasma cholesterol levels on
renal deterioration cannot be excluded in some groups. Treat-
ment by guanfacine led to normal plasma cholesterol levels and
reduced renal lesions, but the protective effect of restricted Na
diet was not associated with plasma cholesterol modifications.
A possible role of renin angiotensin system is suggested by
the results of study II, in contrast with the data of study I.
Enalapril suppresses angiotensin II formation, while guanfacine
stimulates a2 adrenergic receptors, leading to a decrease in
renin secretion. High doses of cicletanine have a diuretic effect
which could enhance renin secretion, but in the present condi-
tions diuresis was unchanged. It remains that in the excision
model ACEI efficiency required stimulation of the renin-angio-
tensin system, showing that the relationship between this
system and renal deterioration is far from understood.
In summary, in the excision remnant kidney model: (1) ACE!
may be ineffective on blood pressure and renal deterioration; (2)
a moderate Na restriction is sufficient to slow renal progression
and to restore the actions of anti-hypertensive drugs; (3) the
renal effect of drugs may vary despite a similar control of blood
pressure; (4) the protective effect of both normal-low Na diet
and ACE! correlates with a substantial attenuation of kidney
enlargement, with lower glomerular hypertrophy and prominent
reduction of tubular dilation.
This study indicates that the two models of nephron reduc-
tion currently used may induce different pathways of renal
deterioration. These differences may provide a useful tool to
investigate the mechanisms underlying the evolution of renal
lesions.
Finally, the present work emphasizes that ACE! efficiency
varies according to the primary renal disease, and is modulated
by the experimental conditions. To what extent the data pre-
sented herein are revelant to humans remains speculative. !n
fact, data on the long-term effects of diet and drugs are still
lacking in patients with renal diseases.
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